Cargando…

Drug Pricing Evolution in Hepatitis C

OBJECTIVE: We aimed to determine the association between the stepwise increase in the sustained viral response (SVR) and Swiss and United States (US) market prices of drug regimens for treatment-naive, genotype 1 chronic hepatitis C virus (HCV) infection in the last 25 years. We identified the follo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vernaz, Nathalie, Girardin, François, Goossens, Nicolas, Brügger, Urs, Riguzzi, Marco, Perrier, Arnaud, Negro, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911078/ https://www.ncbi.nlm.nih.gov/pubmed/27310294 http://dx.doi.org/10.1371/journal.pone.0157098

Ejemplares similares

Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy
por: Girardin, François, et al.
Publicado: (2021)

Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine
por: Girardin, François R., et al.
Publicado: (2018)

Scaling-up hepatitis C screening and treatment in Swiss outpatient psychiatric settings: A cost-effectiveness analysis
por: Girardin, François, et al.
Publicado: (2022)

Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis
por: Vernaz, Nathalie, et al.
Publicado: (2013)

Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications
por: Mattingly, T. Joseph, et al.
Publicado: (2023)

Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review
por: Gastaldi, Giacomo, et al.
Publicado: (2017)

Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals
por: Garcia, Amandine, et al.
Publicado: (2019)

NAFLD and MAFLD as emerging causes of HCC: A populational study
por: Myers, Shuna, et al.
Publicado: (2021)

"Sell an Ox" - The Price of Cure for Hepatitis C in Two Countries
por: Paltiel, Ora, et al.
Publicado: (2019)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020)

Extrahepatic manifestations in hepatitis C virus infection
por: Negro, Francesco, et al.
Publicado: (2017)

The Varying Price of Drugs
Publicado: (1907)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing
por: Vogler, Sabine, et al.
Publicado: (2019)

Hepatitis C virus-induced hepatocellular carcinoma
por: Goossens, Nicolas, et al.
Publicado: (2015)

Membrane transporter proteins: a challenge for CNS drug development
por: Girardin, François
Publicado: (2006)

The impact of early phase price agreements on prices of orphan drugs
por: Nuijten, Mark, et al.
Publicado: (2021)

Peroxisome Proliferator-Activated Receptors and Hepatitis C Virus-Induced Insulin Resistance
por: Negro, Francesco
Publicado: (2009)

Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease
por: Restellini, Sophie, et al.
Publicado: (2018)

Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia
por: Babar, Zaheer Ud Din, et al.
Publicado: (2007)

Price equation captures the role of drug interactions and collateral effects in the evolution of multidrug resistance
por: Gjini, Erida, et al.
Publicado: (2021)

Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
por: Martínez-Sesmero, José M., et al.
Publicado: (2022)

Drug prices: is the sky the limit?
Publicado: (2016)

Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship
por: Messori, Andrea
Publicado: (2016)

The Tariff on Dyestuffs, and Drug Prices
Publicado: (1917)

For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs
por: Shin, Gyeongseon, et al.
Publicado: (2022)

Cardiac adverse reactions associated with psychotropic drugs
por: Girardin, François, et al.
Publicado: (2007)

Variables affecting pricing of orphan drugs: the Italian case
por: Jommi, Claudio, et al.
Publicado: (2021)

Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
por: Rosenthal, Elana S., et al.
Publicado: (2016)

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
por: Iyengar, Swathi, et al.
Publicado: (2016)

Hepatitis C Antibodies among Blood Donors, Senegal, 2001
por: Etard, Jean-François, et al.
Publicado: (2003)

Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients
por: Messori, Andrea
Publicado: (2016)

Pharmacy Benefit Manager Pricing and Spread Pricing for High-Utilization Generic Drugs
por: Mattingly, T. Joseph, et al.
Publicado: (2023)

Drug Utilization and Drug Pricing in the Private Primary Healthcare System in Malaysia: An Employer Price Control Mechanism
por: Zin, Che Suraya, et al.
Publicado: (2020)

The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan
por: Kawakami, Akihiko, et al.
Publicado: (2022)

Lessons From the First Wave of COVID-19: Work-Related Consequences, Clinical Knowledge, Emotional Distress, and Safety-Conscious Behavior in Healthcare Workers in Switzerland
por: Riguzzi, Marco, et al.
Publicado: (2021)

Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program
por: Jones, Eric A., et al.
Publicado: (2019)

The evolution of data pricing: From economics to computational intelligence
por: Hao, Jun, et al.
Publicado: (2023)

A review on hepatitis D: From virology to new therapies
por: Mentha, Nathalie, et al.
Publicado: (2019)

Negotiating prices of drugs for rare diseases
por: Henrard, Séverine, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v8bj3bd7cnsatiet96boq09ar4